Vertex Pharmaceuticals Inc. (VRTX): Price and Financial Metrics
VRTX Price/Volume Stats
Current price | $418.01 | 52-week high | $448.40 |
Prev. close | $417.32 | 52-week low | $310.90 |
Day low | $415.06 | Volume | 1,092,100 |
Day high | $420.67 | Avg. volume | 1,321,226 |
50-day MA | $422.69 | Dividend yield | N/A |
200-day MA | $378.00 | Market Cap | 107.98B |
VRTX Stock Price Chart Interactive Chart >
VRTX POWR Grades
- VRTX scores best on the Quality dimension, with a Quality rank ahead of 98.29% of US stocks.
- VRTX's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- VRTX's current lowest rank is in the Momentum metric (where it is better than 18.05% of US stocks).
VRTX Stock Summary
- VERTEX PHARMACEUTICALS INC's market capitalization of $105,833,060,501 is ahead of 97.69% of US-listed equities.
- VRTX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 462.74 -- higher than 92.72% of US-listed equities with positive expected earnings growth.
- In terms of volatility of its share price, VRTX is more volatile than merely 8.24% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to VERTEX PHARMACEUTICALS INC are LRCX, AMAT, REGN, MU, and ANET.
- VRTX's SEC filings can be seen here. And to visit VERTEX PHARMACEUTICALS INC's official web site, go to www.vrtx.com.
VRTX Valuation Summary
- In comparison to the median Healthcare stock, VRTX's price/sales ratio is 395.45% higher, now standing at 10.9.
- Over the past 243 months, VRTX's price/sales ratio has gone up 3.
Below are key valuation metrics over time for VRTX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
VRTX | 2023-12-29 | 10.9 | 6.3 | 30.2 | 21.7 |
VRTX | 2023-12-28 | 10.9 | 6.4 | 30.4 | 21.8 |
VRTX | 2023-12-27 | 10.9 | 6.4 | 30.3 | 21.8 |
VRTX | 2023-12-26 | 10.9 | 6.4 | 30.3 | 21.7 |
VRTX | 2023-12-22 | 10.8 | 6.3 | 30.1 | 21.6 |
VRTX | 2023-12-21 | 10.7 | 6.3 | 29.8 | 21.3 |
VRTX Growth Metrics
- Its year over year revenue growth rate is now at 23.89%.
- Its 2 year net cashflow from operations growth rate is now at 30.02%.
- The year over year net income to common stockholders growth rate now stands at -11.26%.
The table below shows VRTX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 8,930.7 | 4,129.9 | 3,322 |
2022-09-30 | 8,700.561 | 4,046.493 | 3,273.21 |
2022-06-30 | 8,350.425 | 4,018.212 | 3,194.638 |
2022-03-31 | 7,947.595 | 2,678.645 | 2,451.062 |
2021-12-31 | 7,574.4 | 2,643.5 | 2,342.1 |
2021-09-30 | 7,129.659 | 2,140.039 | 2,176.18 |
VRTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VRTX has a Quality Grade of B, ranking ahead of 86.88% of graded US stocks.
- VRTX's asset turnover comes in at 0.564 -- ranking 66th of 681 Pharmaceutical Products stocks.
- ORGO, MDWD, and CCXI are the stocks whose asset turnover ratios are most correlated with VRTX.
The table below shows VRTX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.564 | 0.879 | 0.725 |
2021-03-31 | 0.565 | 0.881 | 1.066 |
2020-12-31 | 0.589 | 0.881 | 1.053 |
2020-09-30 | 0.619 | 0.880 | 1.013 |
2020-06-30 | 0.618 | 0.877 | 0.796 |
2020-03-31 | 0.607 | 0.872 | 0.605 |
VRTX Price Target
For more insight on analysts targets of VRTX, see our VRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $258.59 | Average Broker Recommendation | 1.54 (Moderate Buy) |
Vertex Pharmaceuticals Inc. (VRTX) Company Bio
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, near Oxford, England. (Source:Wikipedia)
Latest VRTX News From Around the Web
Below are the latest news stories about VERTEX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRTX as an investment opportunity.
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No TomorrowWith a new medicine on the market and plenty of money, Vertex is in great shape. |
3 Monster Stocks to Buy Without Any HesitationThese are easy choices for investors seeking market-beating long-term gains. |
Should You Invest in Bluebird Bio Right Now?After two December share price crashes, there's no evident cure for Bluebird Bio's ills. |
3 Top Stocks to Buy Hand Over Fist Before the End of 2023These are ideal stocks to buy sooner rather than later. |
Editas Just Caught a Break Thanks to Vertex PharmaceuticalsEditas isn't out of the woods yet, but it's better off than before. |
VRTX Price Returns
1-mo | -2.10% |
3-mo | 2.73% |
6-mo | 20.21% |
1-year | 33.91% |
3-year | 96.26% |
5-year | 127.24% |
YTD | 2.73% |
2023 | 40.90% |
2022 | 31.50% |
2021 | -7.08% |
2020 | 7.94% |
2019 | 32.13% |
Continue Researching VRTX
Want to see what other sources are saying about Vertex Pharmaceuticals Inc's financials and stock price? Try the links below:Vertex Pharmaceuticals Inc (VRTX) Stock Price | Nasdaq
Vertex Pharmaceuticals Inc (VRTX) Stock Quote, History and News - Yahoo Finance
Vertex Pharmaceuticals Inc (VRTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...